Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Atherosclerosis and Thrombosis"
DOI: 10.5551/jat.63659
Abstract: Aim: Pemafibrate is a highly selective agonist for peroxisome proliferator-activated receptor (PPAR)-α, a key regulator of lipid and glucose metabolism. We compared the efficacy and safety of pemafibrate with those of bezafibrate, a nonselective PPAR-α… read more here.
Keywords: pemafibrate; safety pemafibrate; randomized crossover; pemafibrate bezafibrate ... See more keywords